Microfibril Associated Protein 4 (MFAP4) is supressed by smoking and associate to dyspnea in COPD patients  by Johansson, Sofie L. et al.
Abstracts S5lung, COPD and emphysema. Immunohistochemical findings were correlated
with the clinical data.
Damaged alveolar walls formed distal alveolar distensions, which contained
a-SMA positive cells as well as occasionally tenascin-C and EDA-fibronectin.
a-SMA-positive cells located in bronchi as foci of variable sizes. Tenascin-C
expression in bronchi was analyzed as previously showing positivity a) in
basal cells and basement membrane (BM), b) in basal cells plus BM plus
stroma underneath BM, and c) in abovementioned areas plus widely in the
stroma (2). Most of the bronchioles revealed positive cells for a-SMA, while
the expression for tenascin-C and EDA-fibronectin was mainly negative. The
number of a-SMA positive distal alveolar distensions was higher in non-
smokers and normal lung than in smokers and COPD. The number of a-SMA
positive foci in bronchi associated with obstruction.
We concluded that a-SMA-positive distensions in alveolar walls might be
involved in regenerative process of alveoli in normal and diseased lung.
Moreover, foci of a-SMA positive cells in bronchial walls together with the
excess of tenascin-C seemed to reflect remodelling process of large airways
in COPD.
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During wound healing processes fibroblasts accounts for wound closure by
adopting a contractile phenotype and produce extracellular matrix (ECM)
molecules. During normal wound healing the process is terminated when the
wound has healed and the initial trigger disappears. However when the
trigger persists, as is the case in COPD with the repeated exposure of
cigarette smoke, the wound healing process becomes pathological and the
fibroblast phenotype is likely to be altered. Our aim was to investigate the
repair capability, defined as ECM production and contractility, in centrally
(bronchial) and distally (alveolar) derived fibroblasts from severe COPD
patients and control subjects.
The repair functions were different in centrally and distally derived
fibroblasts from COPD patients compared to the corresponding cells from
control subjects. Distally derived fibroblasts from COPD patients were more
contractile and this was dependent on increased ROCK1 activity. In addition,
these cells had enhanced production of the proteoglycan versican. Versican
have been suggested to interfere with de novo synthesis of elastin and may
thus be important in formation of emphysema. Centrally derived fibroblasts
from COPD patients had a lower basal production of the basement mem-
brane-stabilizing proteoglycan perlecan which may indicate alterations of
the bronchial basement membrane in COPD. To summarize, our results sug-
gest that fibroblasts from COPD patients have altered repair functions.
Importantly, there was a difference in function between bronchial and alve-
olar fibroblasts which may reflect the different pathological processes in
these sites.
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Background: MFAP4 is a glycoprotein, co-localized with elastin and microfi-
brils in elastic fibres (Schlosser, Thomsen et al. (2006)). MFAP4 knock-out
mice develop mild emphysema (not yet published data). We hypothesized
that circulating MFAP4 reflects elastin degradation and can be used as a
marker of emphysema severity.
Methods: Plasma levels of MFAP4 (pMFAP4) were determined by Alphalisa
assay in 76 Danish COPD patients from the multicentre ECLIPSE study,
(Vestbo, Anderson et al. 2008) 50 smokers and 54 non-smokers. Controls
were healthy blooddonors. Associations between ln-transformed pMFAP4
levels and clinical outcomes were assessed by Pearson product moment cor-
relation test and multiple regression analysis. Age, gender, packyears and
carbonmonnoxide (as a indicator of current smoking) were included as
covariates.
Results: Levels of lnMFAP4 were significantly lower in smokers (mean:364ng/
mL) than in non-smokers (471 ng/mL) and COPD patients (457 ng/mL).
LnMFAP4 associated significantly with MMRC (Modified Medical Research
Council score) in COPD patients (b: 0.09 p<0.05). There was a tendency of
association between the composite BODE index (BMI, Obstruction index, Dys-
pnea score and Exercise capacity), it was borderline significant when adjust-
ing for covariates (b:0.03 p:0.07). LnpMFAP4 did not associate significantly
with FEV1 (b:-0.002 pZ0.24) or obstruction index (b:-0.004 pZ0.13).
Conclusion: MFAP4 plasma levels are supressed by smoking, and are associ-
ated to dyspnea in COPD patients.
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Smoking is the most important environmental risk factor for the develop-
ment of COPD. Computer tomography (CT) imaging provides means of
quantifying pulmonary structure and function. We hypothesized that the
inflammation in smokers may be mirrored by an altered attenuation on high
resolution CT (HRCT).
Forty smokers with normal lung function (20 men, 20 women, age mean 54;
range 45-65; 3512 pack years, 40 healthy neversmokers, age 57 (45-65) and 40
patientswithCOPD,GOLD stage I-II, age 59 (45-65) (3811 pack year, 31 current
smokers and 9 exsmokers) underwent inspiratory HRCT scans . Values between
-750 and -900 HUwere considered as high attenuation areas and the percentage
of the lung volumewith this attenuation range was calculated. Bronchoalveolar
lavage, BAL, was performed according to a standardized protocol. Cell
concentration and differential cell counts in BAL fluid were recorded.
The percentage of lung area with high attenuation was increased in smokers
(44%  5.7; mean SD) compared to neversmokers (38%  5.6) and COPD
exsmokers (33%  4.5) (p<0.001 and p<0.05 respectively) indicating denser
lungs in smokers. COPD current smokers (41%  5.0) did not differ from that
of smokers with normal lung function. A significant positive correlation
(p<0.001) between cell concentration in BAL and HRCT areas with high
density was found in current smokers. There was no significant correlation
between cell concentrations in BAL and HRCT density in neversmokers and
COPD exsmokers. Female neversmokers had denser lungs than males (40% 
1.3 vs 36% 1.3, pZ0.03). This was also the case for smokers with normal
lung function (females 46%  1.3 vs males 42% +1.2; p<0.04).
The increased density in smokers compared to nonsmokers may mirror an
inflammatory response induced by cigarette smoke and is correlated to
current smoking status rather than smoking history. This hypothesis is
strengthened by a positive correlation between lung attenuation and cell
concentration in the lower respiratory tract. A gender difference was found
suggesting a more intense inflammation in female smokers than in males.
